Dolutegravir sodium salt

Description

Dolutegravir sodium salt · CAS 1051375-19-9 · C20H18F2N3NaO5. UNII 1Q1V9V5WYQ.

Identification

Computed Descriptors

GHS Hazard Classification

Documented Uses

• Dolutegravir (brand names: Tivicay and Tivicay PD) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV in combination with:
• Other HIV medicines in children and infants who are at least 4 weeks of age and weigh at least 6.6 lb (3 kg) and who meet specific requirements, as determined by a health care provider; or
• Rilpivirine (brand name: Edurant) as a complete regimen in adults who meet specific requirements, as determined by a health care provider. (A fixed-dose combination tablet containing dolutegravir and rilpivirine [brand name: Juluca] is also available.)
• Dolutegravir is always used in combination with other HIV medicines.
• Integrase Strand Transfer Inhibitor (INSTIs)
• Inhibitors of HIV INTEGRASE, an enzyme required for integration of viral DNA into cellular DNA.

Synonyms

DOLUTEGRAVIR SODIUM; 1051375-19-9; Dolutegravir sodium salt; TIVICAY PD; 1Q1V9V5WYQ; CHEBI:76007; GSK-1349572A; JULUCA COMPONENT DOLUTEGRAVIR SODIUM; TRIUMEQ COMPONENT DOLUTEGRAVIR SODIUM; DTXSID201027849; RefChem:56965; DTXCID001513426; Tivicay; Dolutegravir sodium [USAN]; Dolutegravir (sodium); GSK1349572 sodiuM salt

Frequently Asked Questions

What are the CAS number and molecular formula of Dolutegravir sodium salt?

CAS 1051375-19-9; molecular formula C20H18F2N3NaO5; molecular weight — g/mol.

What other names is Dolutegravir sodium salt known by?

DOLUTEGRAVIR SODIUM, 1051375-19-9, Dolutegravir sodium salt, TIVICAY PD, 1Q1V9V5WYQ, CHEBI:76007.

Is Dolutegravir sodium salt classified as hazardous?

Hazard statements reported: H400, H410, H302.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.